Molecules of the Month – June 2023
Drug Hunter
JULY 21, 2023
danuglipron – An oral GLP-1-RA full agonist in Phase IIb clinical trials for obesity and Phase II trials for type 2 diabetes mellitus, identified through sensitized cell high-throughput screening and optimization, originated from Pfizer. Request a trial to check out substructure search and more features. Not a member?
Let's personalize your content